RDS03-94

RDS03-94
Clinical data
Other namesRDS3-094
Identifiers
  • 1-[(2S,6R)-4-[2-[bis(4-fluorophenyl)methylsulfanyl]ethyl]-2,6-dimethylpiperazin-1-yl]propan-2-ol
CAS Number
PubChem CID
ChEMBL
Chemical and physical data
FormulaC24H32F2N2OS
Molar mass434.59 g·mol−1
3D model (JSmol)
  • C[C@@H]1CN(C[C@@H](N1CC(C)O)C)CCSC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
  • InChI=1S/C24H32F2N2OS/c1-17-14-27(15-18(2)28(17)16-19(3)29)12-13-30-24(20-4-8-22(25)9-5-20)21-6-10-23(26)11-7-21/h4-11,17-19,24,29H,12-16H2,1-3H3/t17-,18+,19?
  • Key:GVCYHQGCEQPNRF-DFNIBXOVSA-N

RDS03-94, or RDS3-094, is an atypical dopamine reuptake inhibitor that was derived from the wakefulness-promoting agent modafinil.

It has substantially higher affinity and potency in terms of dopamine transporter (DAT) inhibition than modafinil (Ki = 39.4 nM vs. 8,160 nM) whilst retaining the atypical DAT blocker profile of modafinil. However, RDS03-94 also has high affinity for the sigma σ1 receptor (Ki = 2.19 nM).

RDS03-94 shows some reversal of tetrabenazine-induced motivational deficits in animals and hence may have the capacity to produce pro-motivational effects. However, it appears to be less effective than certain other related agents, like JJC8-088.

RDS03-94 is under development for the treatment of psychostimulant use disorder. The drug was first described in the scientific literature in 2020.

See also